Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05755191




Registration number
NCT05755191
Ethics application status
Date submitted
22/02/2023
Date registered
6/03/2023
Date last updated
21/03/2024

Titles & IDs
Public title
A Study to Assess NEU-411 in Healthy Participants
Scientific title
A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Secondary ID [1] 0 0
NEU-411-PD101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - NEU-411
Treatment: Drugs - Placebo

Experimental: NEU-411 - Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)

Placebo Comparator: Placebo - Part A: Single-ascending dose cohorts; food effect; Part B: Multiple-ascending dose cohorts (7 days)


Treatment: Drugs: NEU-411
Oral Doses

Treatment: Drugs: Placebo
Oral Doses
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Evaluate the safety and tolerability of single dosing, food effect and multiple oral doses of NEU-411 in healthy subjects
Timepoint [1] 0 0
Up to 7 days of dosing
Secondary outcome [1] 0 0
PK parameter
Timepoint [1] 0 0
Up to 7 days of dosing
Secondary outcome [2] 0 0
PK parameter
Timepoint [2] 0 0
Up to 7 days of dosing
Secondary outcome [3] 0 0
PK parameter
Timepoint [3] 0 0
Up to 7 days of dosing
Secondary outcome [4] 0 0
PK parameter
Timepoint [4] 0 0
Up to 7 days of dosing
Secondary outcome [5] 0 0
PK parameter
Timepoint [5] 0 0
Up to 7 days of dosing
Secondary outcome [6] 0 0
PK parameter
Timepoint [6] 0 0
Up to 7 days of dosing
Secondary outcome [7] 0 0
PK parameter
Timepoint [7] 0 0
Up to 7 days of dosing
Secondary outcome [8] 0 0
PK parameter
Timepoint [8] 0 0
Up to 7 days of dosing
Secondary outcome [9] 0 0
PK parameter
Timepoint [9] 0 0
Up to 7 days of dosing

Eligibility
Key inclusion criteria
- Subjects for standard cohorts must be 18-80 years, inclusive, at the time of signing
the informed consent;

- Subjects who are in good general health with no clinically relevant abnormalities
based on the medical history, physical examinations, neurological examinations,
clinical laboratory evaluations (hematology and clinical chemistry)

- Subjects who have a body mass index (BMI) of 18-32 kg/m2(inclusive);

- Male subjects are eligible to participate if they are rendered surgically sterile (at
least 6 months), or agree to the following during the study and for at least 30 days
after the last dose of study drug:

- Refrain from donating sperm;

AND, either:

Be abstinent from heterosexual intercourse as their preferred and usual lifestyle
(abstinent on a long term and persistent basis) and agree to remain abstinent; OR Agree to
use a male condom (contraception/barrier) and should also be advised of the benefit for a
female partner to use an acceptable, highly effective method of contraception as a condom
may break or leak when having sexual intercourse;

• Female subjects are eligible to participate if they are not pregnant or breastfeeding,
subject to one of the following:

- Women of childbearing potential (WOCBP), defined as women physiologically capable of
becoming pregnant, must have a negative serum pregnancy test at the Screening visit
and a negative urine pregnancy test on Day -1; WOCBP must agree to use an acceptable,
highly effective contraceptive method from Screening until 30 days after the last dose
of study treatment (see Section 11.3); OR

- Menopausal women must have an elevated serum follicle-stimulating hormone level (FSH)
level at Screening; if the FSH is not elevated, they are considered to be of
childbearing potential (unless permanently sterile) and must have a negative serum
pregnancy test at Screening and a negative urine pregnancy test on Day -1
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- History of clinically significant hematological, renal, pancreatic, gastrointestinal,
hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or
other major disorders

- History of clinically significant abnormal chest x-ray

- Clinically significant neurologic disorder

- Contraindications to undergo a lumbar puncture (only for subjects participating in the
MAD)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/05/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/07/2024
Actual
Sample size
Target
147
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Neuron23 Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD),
food effect (FE),multiple ascending dose (MAD), drug-drug interaction study, and
bioavailability - bio-equivalence study of orally administered NEU-411 in healthy subjects
Trial website
https://clinicaltrials.gov/ct2/show/NCT05755191
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Sam Jackson, MD
Address 0 0
Country 0 0
Phone 0 0
510-998-4122
Fax 0 0
Email 0 0
sam.jackson@neuron23.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05755191